Trials / Unknown
UnknownNCT04664647
The Clinical Features of Combined Central and Peripheral Demyelination
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The investigators conduct this study to clarify the clinical features and to evaluate the prevalence of anti-nodal/paranodal antibodies of patients with combined central and peripheral demyelination (CCPD) .
Detailed description
The investigators will review the clinical manifestation, laboratory test results, electrophysiological examination and neuroimaging findings of patients with CCPD. And we will detect antibodies to aquaporin 4(AQP4), myelin oligodendrocyte glycoprotein (MOG), neurofascin-155 (Nfasc155), neurofascin-186 (Nfasc186), and myelin-associated glycoprotein (MAG) in patients with CCPD.
Conditions
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2020-12-01
- Completion
- 2021-01-01
- First posted
- 2020-12-11
- Last updated
- 2020-12-16
Source: ClinicalTrials.gov record NCT04664647. Inclusion in this directory is not an endorsement.